Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes

J Sex Med. 2006 Mar;3(2):253-64; discussion 264-5, author reply 265-6. doi: 10.1111/j.1743-6109.2006.00207.x.

Abstract

Introduction: Hypogonadism is often associated with diabetes and both conditions represent major risk factors for erectile dysfunction (ED).

Aim: To investigate the role of hypogonadism on phosphodiesterase type 5 (PDE5) expression and sildenafil responsiveness in diabetes.

Methods: Two different models of experimental diabetes were used: (i) alloxan-induced diabetic rabbit; and (ii) streptozotocin (STZ)-induced diabetic rat. In both experimental models, animals were separated into three groups: control, diabetic, diabetic supplemented with testosterone (T) enanthate. Rabbits were used for "in vitro" experiments. Conversely, each rats group was further subdivided: no further treatment or acute sildenafil dosing (25 mg/kg, 1 hour before "in vivo" electrical stimulation [ES]).

Main outcome measure: Erectile capacity was evaluated either by "in vitro" contractility study (alloxan-induced diabetic rabbit) and "in vivo" evaluation of erectile response elicited by ES of cavernous nerve (STZ-induced diabetic rats). Also endothelial nitric oxide synthase, neural nitric oxide synthase (nNOS), and PDE5 protein (Western blot) and mRNA (quantitative real-time reverse transcriptase polymerase chain reaction [RT-PCR]) expression were measured in rat penile samples of each group.

Results: In both models, hypogonadism was observed, characterized by reduced T and atrophy of androgen-dependent accessory glands. T substitution completely reverted hypogonadism and diabetes-induced penile hyposensitivity to "in vitro" (acetylcholine, rabbit) or "in vivo" (ES, rat) relaxant stimuli, along with nNOS expression, which was reduced (P < 0.05) in STZ rats. In diabetic animals, T substitution reinstated sildenafil-induced enhancement of both "in vitro" nitric oxide donor (NCX 4040) relaxant effect (rabbit) and "in vivo" ES-induced erection (rat). PDE5 was reduced in diabetic STZ rats (P < 0.05) and normalized by T. In STZ rats, sodium nitroprusside (SNP) intracavernous injection induced a more sustained erection than in control rats, which was no further enhanced by sildenafil. T substitution normalized both hyper-responsiveness to SNP and sildenafil efficacy.

Conclusion: In two models of diabetes T deficiency underlies biochemical alterations leading to ED. Normalizing T in diabetes restores nNOS and PDE5, and reinstates sensitivity to relaxant stimuli and responsiveness to sildenafil.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Alloxan
  • Animals
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Diabetes Mellitus, Experimental / complications*
  • Disease Models, Animal
  • Endothelium, Vascular / metabolism
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / etiology
  • Erectile Dysfunction / metabolism
  • Hypogonadism / drug therapy
  • Hypogonadism / etiology
  • Hypogonadism / metabolism
  • Male
  • Nitric Oxide Synthase / metabolism
  • Penile Erection / drug effects
  • Phosphoric Diester Hydrolases / metabolism
  • Piperazines / administration & dosage*
  • Piperazines / pharmacology
  • Purines
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sildenafil Citrate
  • Streptozocin
  • Sulfones
  • Testosterone / administration & dosage
  • Testosterone / analogs & derivatives*
  • Testosterone / pharmacology

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Testosterone
  • Streptozocin
  • Alloxan
  • testosterone enanthate
  • Sildenafil Citrate
  • Nitric Oxide Synthase
  • Phosphoric Diester Hydrolases
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Pde5a protein, rat